Latest Angiodynamics (ANGO) Headlines Wednesday
Post# of 28
Posted On: 03/12/2014 5:54:32 PM
Latest Angiodynamics (ANGO) Headlines
Wednesday's Top Upgrades (and Downgrades)
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 12, 11:00AM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature downgrades for clothiers Urban Outfitters and American Eagle Outfitters . But...
Upgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Mar 12, 7:05AM CDT
Angiodynamics (NASDAQ:ANGO) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $15.85 on volume of 175,000 shares, above average daily volume of 146,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
AngioDynamics Receives Expanded FDA Clearance for AngioVac
GlobeNewswire - Tue Mar 11, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for its AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.
AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.
AngioDynamics Receives FDA Clearance for DuraMax Dialysis Catheter With BioFlo Technology to Reduce Catheter-Related Thrombus
GlobeNewswire - Fri Mar 07, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.
AngioDynamics Updates U.S. Tip Location Strategy
GlobeNewswire - Fri Mar 07, 2:59AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) rejected its distribution partner, Medcomp Inc.'s, 510(k) application for the Celerity tip location system.
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).
AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 03, 6:00AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to address the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, at 4:15 p.m. ET. The conference will be held at the Loews Hotel in Miami, Fla.
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
Fresenius Medical Care Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:20AM CST
For full-year 2013, FMS reported a 6.5% fall in net earnings to $1.1 billion and a 6% drop in net earnings per share to $1.83.
Q4 Earnings Beat at AmSurg, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:10AM CST
AmSurg Corp.'s fourth-quarter 2013 EPS from continuing operations climbed 22% year over year to 60 cents.
Balanced View on Omnicell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 1:50PM CST
On Feb 24, 2014, we issued an updated research report on Omnicell.
Wider Q4 Loss, Poor Outlook at Volcano Corp. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:00AM CST
Volcano Corporation reported adjusted net loss of 29 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate loss of 24 cents per share.
Balanced View on PetMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 5:00PM CST
On Feb 19, 2014, we issued an updated research report on PetMed Express.
Updated Research Report on Cepheid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 2:00PM CST
Recently, we issued an updated research report on Cepheid.
Why Cynosure (CYNO) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:54AM CST
Cynosure has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
Pacific Biosciences (PACB) Jumps: Stock Moves 8.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:46AM CST
Pacific Biosciences was a big mover last session, with shares rising over 8%.
Masimo Q4 Earnings Meet Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 2:43PM CST
For full year 2013, adjusted earnings per share rose 11.5% to $1.16, in line with the Zacks Consensus Estimate.
NASSCORP Holds Awareness Forum
by Namoteekollie From Bong County - All Africa Global Media - Thu Feb 13, 6:01AM CST
An interactive forum between employers and employees organized by the National Social Security and Welfare Corporation (NASSCORP) has ended in Gbarnga, Bong County with the objective of explaining the day-to-day operations of the corporation to employees and employers for better understanding of the entity.
Wednesday's Top Upgrades (and Downgrades)
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 12, 11:00AM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature downgrades for clothiers Urban Outfitters and American Eagle Outfitters . But...
Upgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Mar 12, 7:05AM CDT
Angiodynamics (NASDAQ:ANGO) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $15.85 on volume of 175,000 shares, above average daily volume of 146,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
AngioDynamics Receives Expanded FDA Clearance for AngioVac
GlobeNewswire - Tue Mar 11, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for its AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.
AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.
AngioDynamics Receives FDA Clearance for DuraMax Dialysis Catheter With BioFlo Technology to Reduce Catheter-Related Thrombus
GlobeNewswire - Fri Mar 07, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.
AngioDynamics Updates U.S. Tip Location Strategy
GlobeNewswire - Fri Mar 07, 2:59AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) rejected its distribution partner, Medcomp Inc.'s, 510(k) application for the Celerity tip location system.
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).
AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 03, 6:00AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to address the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, at 4:15 p.m. ET. The conference will be held at the Loews Hotel in Miami, Fla.
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
Fresenius Medical Care Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:20AM CST
For full-year 2013, FMS reported a 6.5% fall in net earnings to $1.1 billion and a 6% drop in net earnings per share to $1.83.
Q4 Earnings Beat at AmSurg, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:10AM CST
AmSurg Corp.'s fourth-quarter 2013 EPS from continuing operations climbed 22% year over year to 60 cents.
Balanced View on Omnicell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 1:50PM CST
On Feb 24, 2014, we issued an updated research report on Omnicell.
Wider Q4 Loss, Poor Outlook at Volcano Corp. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:00AM CST
Volcano Corporation reported adjusted net loss of 29 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate loss of 24 cents per share.
Balanced View on PetMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 5:00PM CST
On Feb 19, 2014, we issued an updated research report on PetMed Express.
Updated Research Report on Cepheid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 2:00PM CST
Recently, we issued an updated research report on Cepheid.
Why Cynosure (CYNO) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:54AM CST
Cynosure has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
Pacific Biosciences (PACB) Jumps: Stock Moves 8.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:46AM CST
Pacific Biosciences was a big mover last session, with shares rising over 8%.
Masimo Q4 Earnings Meet Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 2:43PM CST
For full year 2013, adjusted earnings per share rose 11.5% to $1.16, in line with the Zacks Consensus Estimate.
NASSCORP Holds Awareness Forum
by Namoteekollie From Bong County - All Africa Global Media - Thu Feb 13, 6:01AM CST
An interactive forum between employers and employees organized by the National Social Security and Welfare Corporation (NASSCORP) has ended in Gbarnga, Bong County with the objective of explaining the day-to-day operations of the corporation to employees and employers for better understanding of the entity.
(0)
(0)AngioDynamics Inc. (ANGO) Stock Research Links
Scroll down for more posts ▼